1,061 results on '"Kastelein, John J.P."'
Search Results
52. Screening and treatment of familial hypercholesterolemia – Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014)
53. Gonadal steroids, gonadotropins and DHEAS in young adults with familial hypercholesterolemia who had initiated statin therapy in childhood
54. Efficacy and Safety of Ezetimibe Monotherapy in Children with Heterozygous Familial or Nonfamilial Hypercholesterolemia
55. Nonpharmacological Lipoprotein Apheresis Reduces Arterial Inflammation in Familial Hypercholesterolemia
56. Pharmacotherapy for children with elevated levels of lipoprotein(a): future directions
57. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial
58. Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation
59. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial
60. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1
61. Response by Kusters et al to Letter Regarding Article, “Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)”
62. Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein–Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab
63. A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH
64. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
65. Novel lipid modifying drugs to lower LDL cholesterol
66. Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy—Brief Report
67. Intervention to Improve Adherence to Lipid-Lowering Medication and Lipid-Levels in Patients With an Increased Cardiovascular Risk
68. Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Severe Hypertriglyceridemia (SHTG) – Initial Baseline data from an Ongoing Phase 2 Study
69. Resmetirom (MGL-3196) in Patients With Heterozygous Familial Hypercholesterolemia
70. EVOLOCUMAB IN PEDIATRIC HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM THE HAUSER OPEN-LABEL EXTENSION STUDY
71. Lipoprotein-associated phospholipase A 2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: Effect of pravastatin
72. Obesity and Dyslipidemia
73. Adiponectin and Risk of Coronary Heart Disease in Apparently Healthy Men and Women (from the EPIC-Norfolk Prospective Population Study)
74. 459 Evaluation of LDL-C reductions by siRNA treatment with inclisiran in patients with diabetes mellitus, metabolic syndrome or neither
75. Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study
76. Contributors
77. What does the future hold for cholesteryl ester transfer protein inhibition?
78. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
79. Prolactin fragmentation by trophoblastic matrix metalloproteinases as a possible contributor to peripartum cardiomyopathy and pre-eclampsia
80. Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: The EPIC-Norfolk prospective population study
81. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: A 12-week, multicenter, randomized, double-blind, controlled trial
82. Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trial)
83. Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia
84. Beyond the Usual Suspects: Expanding on Mutations and Detection for Familial Hypercholesterolemia
85. Global Perspectives of Familial Hypercholesterolemia
86. PCSK9 Inhibitors and Cardiovascular Events
87. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
88. Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis, and current and future treatment perspectives
89. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
90. Long-Term Statin Treatment in Children with Familial Hypercholesterolemia: More Insight into Tolerability and Adherence
91. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome
92. Comparative Effect of Atorvastatin (80 mg) Versus Simvastatin (20 to 40 mg) in Preventing Hospitalizations for Heart Failure in Patients With Previous Myocardial Infarction
93. Comparison of Efficacy and Safety of Atorvastatin (80 mg) to Simvastatin (20 to 40 mg) in Patients Aged
94. Usefulness of Genetic Polymorphisms and Conventional Risk Factors to Predict Coronary Heart Disease in Patients With Familial Hypercholesterolemia
95. The Genetics of High-Density Lipoprotein Metabolism: Clinical Relevance for Therapeutic Approaches
96. Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease
97. Safety and Tolerability of Dalcetrapib
98. New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B:JACC Focus Seminar 1/4
99. Efficacy and Safety of Coadministration of Ezetimibe and Simvastatin in Adolescents With Heterozygous Familial Hypercholesterolemia
100. Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.